scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0145-2126(03)00185-1 |
P8608 | Fatcat ID | release_rui4xmzikncu5gvsn3du5tnmsa |
P698 | PubMed publication ID | 14654076 |
P50 | author | Ayalew Tefferi | Q66370740 |
P2093 | author name string | Hoffbrand AV | |
Butterfield JH | |||
Pardanani A | |||
P2860 | cites work | Treatment of cutaneous mastocytosis | Q28192647 |
Mastocytosis: mediator-related signs and symptoms | Q33147535 | ||
Response of severe systemic mastocytosis to interferon alpha | Q33502416 | ||
Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy | Q34263013 | ||
Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes | Q34529077 | ||
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria | Q35101794 | ||
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product | Q38315689 | ||
Significance of systemic mast cell disease with associated hematologic disorders | Q39715028 | ||
2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies | Q40622052 | ||
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations | Q40748765 | ||
Treatment of systemic mast-cell disease with cladribine | Q43527780 | ||
Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients | Q44242600 | ||
Response to interferon alfa-2b in a patient with systemic mastocytosis | Q67531413 | ||
Long-term follow-up of indolent mastocytosis in adults | Q70917154 | ||
Treatment of three patients with systemic mastocytosis with interferon alpha-2b | Q71709213 | ||
Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine | Q72679379 | ||
2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia | Q73892991 | ||
Adult-onset urticaria pigmentosa and systemic mast cell disease | Q93655431 | ||
P433 | issue | 2 | |
P921 | main subject | mast cell | Q191989 |
P304 | page(s) | 127-131 | |
P577 | publication date | 2004-02-01 | |
P1433 | published in | Leukemia Research | Q15716445 |
P1476 | title | Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine | |
P478 | volume | 28 |
Q33366921 | 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome |
Q82207899 | A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis |
Q46227941 | Advanced mast cell disease: an Italian Hematological Multicenter experience |
Q43225680 | Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. |
Q92276375 | Clinical potential of midostaurin in advanced systemic mastocytosis |
Q38661465 | Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial |
Q36730397 | International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. |
Q55286285 | KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia. |
Q37195681 | KIT and mastocytosis |
Q38045311 | Mast Cell Leukaemia: c-KIT Mutations Are Not Always Positive |
Q36839953 | Mastocytosis: advances in diagnosis and treatment. |
Q35994902 | Mastocytosis: pathology, genetics, and current options for therapy |
Q38582624 | Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease |
Q47727992 | Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis |
Q36583570 | Novel approaches in the treatment of systemic mastocytosis |
Q26748784 | Pharmacological treatment options for mast cell activation disease |
Q59810100 | Preclinical human models and emerging therapeutics for advanced systemic mastocytosis |
Q52731268 | Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: a single-center experience. |
Q46575598 | Systemic mastocytosis |
Q83304407 | Systemic mastocytosis |
Q45058347 | Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management |
Q37992835 | Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management |
Q38110527 | Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management |
Q38358282 | Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management |
Q39267824 | Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management |
Q36182749 | Systemic mastocytosis: bone marrow pathology, classification, and current therapies |
Q46727970 | Thalidomide in advanced mastocytosis |
Q33406035 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study |
Q42234623 | The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm |